Logo image
Back
Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary
Journal article   Peer reviewed

Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary

Kiran Turaka, Daniel Kietz, Lakshmanan Krishnamurti, Ellen Mitchell, Hannah Scanga, Valeria L N Fu and Christin Sylvester
Journal of AAPOS, v 18(4), pp 396-398
01 Aug 2014
DOI: https://doi.org/10.1016/j.jaapos.2014.03.007
PMID: 25173906
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Adolescent Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Agents - therapeutic use Arrestin - immunology Autoantibodies - blood Autoantigens - immunology Color Vision Defects Drug Therapy, Combination Electroretinography Evoked Potentials, Visual Female Fluorescein Angiography Glucocorticoids - therapeutic use Humans Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Methylprednisolone - therapeutic use Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Ovariectomy Paraneoplastic Syndromes, Ocular - diagnosis Paraneoplastic Syndromes, Ocular - drug therapy Prednisolone - therapeutic use Rituximab Teratoma - pathology Teratoma - surgery Tomography, Optical Coherence Visual Acuity
A 14-year-old African American girl presented with diminished vision in both eyes 1 week after undergoing an oophorectomy for a right ovarian mass. Systemic metastatic work-up was negative. Visual acuity was 20/40 in the right eye and 20/50 in the left eye. Slit-lamp biomicroscopy was unremarkable in both eyes. Fundus examination showed diffuse patchy areas of retinal pigment epithelial atrophy in the macula and peripheral retina bilaterally. Color vision had decreased in each eye. Electroretinography revealed nondetectable rod and cone responses. Both pattern and flash visual evoked potential (VEP) testing showed delayed latency in both eyes. She was treated with pulse intravenous methylprednisolone for 3 days along with intravenous immunoglobulins and rituximab, followed by systemic prednisolone and biweekly intravenous immunoglobulins and rituximab for 3 months. Antiretinal autoantibodies against 48-kDa (arrestin) and 64-kDa and 94-kDa proteins were positive, suggestive of carcinoma-associated retinopathy. After 3 months, visual acuity was 20/40 in each eye with improvement in color vision and VEP findings.

Metrics

16 Record Views
11 citations in Web of Science
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Ophthalmology
Pediatrics
Logo image